High materiality9/10
Latigo Biotherapeutics initiated with a Buy at Guggenheim
Why it may matterVerify against the original reporting
Buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim initiates LTGO with a Buy rating; target $50; current price $22.02.
- Guggenheim initiates LTGO with Buy; target $50; price $22.02.
Key facts
- 01
Target: $50
- 02
Posted price: $22.02
- 03
Analyst firm: Guggenheim
- 04
Analyst: Yatin Suneja
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.